Identifying patients at risk of cardiovascular disease: A pharmacist-managed screening event for union workers and their dependents

Journal of the American Pharmacists Association

Volumn 49, Issue 4, 2009, Pages 549-553

  Liu, Yifei ^a   McDonough, Randal P ^b   Carruthers, Kara M ^c   Doucette, William R ^d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Towncrest Pharmacy   (United States)

^c Main at Locust Pharmacy Clinic and Medical Supply   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Cardiovascular disease; Cholesterol; Community pharmacy; Managed care

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ELECTRICITY; FEMALE; HUMAN; HYPERTENSION; MALE; MASS SCREENING; MIDDLE AGED; OCCUPATIONAL HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PHARMACY; RISK ASSESSMENT; RISK FACTOR; SANITATION; TRADE UNION; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COMMUNITY PHARMACY SERVICES; DYSLIPIDEMIAS; ELECTRICITY; FEMALE; HUMANS; HYPERTENSION; IOWA; LABOR UNIONS; LIPOPROTEINS, HDL; MALE; MASS SCREENING; MIDDLE AGED; OCCUPATIONAL HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; SANITARY ENGINEERING; YOUNG ADULT;

EID: 67651049167     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.08024     Document Type: Article

References (17)

1. American Heart Association. Heart disease and stroke statistics: 2007 update. Dallas, TX: American Heart Association; 2007.
2. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
3. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:157-65.
4. Ibrahim OM, Catania PN, Mergener MA, Supernaw RB. Outcome of cholesterol screening in a community pharmacy. DICP. 1990;24:817-21.
5. Magnum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc. 2003;43:50-4.
6. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med. 2003;25:144-53.
7. Snella KA, Canales AE, Irons BK, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high risk individuals. J Am Pharm Assoc. 2006;46:370-7.
8. National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary. Bethesda, MD: National Institutes of Health; 2001 [NIH publ. no. 01-3670].
9. National Heart, Lung, and Blood Institute, National Institutes of Health. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: complete report. Bethesda, MD: National Institutes of Health; 2004 [NIH publ. no. 04-5230].
10. Kamal KM, Madhavan SS, Maine LL. Pharmacy and immunization services: pharmacists' participation and impact. J Am Pharm Assoc. 2003;43:470-82.
11. Centers for Disease Control and Prevention. Preventing heart disease and stroke. Accessed at www.cdc.gov/nccdphp/publications/factsheets/Prevention/cvh. htm, November 22, 2005.
12. Wilson JB, Osterhaus MC, Farris KB, et al. A cost-benefit analysis of a cardiovascular wellness program in a self-insured company from the provider's perspective. J Am Pharm Assoc. 2005;45:588-92.
13. John EJ, Vavra T, Farris KB, et al. Workplace-based cardiovascular risk management by community pharmacists: impact on blood pressure and lipid level. Pharmacotherapy. 2006;26:1511-7.
14. Struthers AD, MacFadyen R, Fraser C, et al. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol. 1999;34:2072-7.
15. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 1997;241:317-25.
16. Ornstein SM, Jenkins RG. Quality of care for chronic illness in primary care: opportunity for improvement in process and outcome measures. Am J Manag Care. 1999;5:621-7.
17. Butler J, Arbogast PG, Belue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589-95.